Foodstate vitamin C complex may beneficially affect haemostasis and fibrin network structure in hyperlipidaemic patients.
This randomized, placebo-controlled, double-blind, crossover study on 25 free-living hyperlipidaemic volunteers aspired to prove the hypothesis that supplementation for 8 weeks with a FoodState Vitamin C complex (500 mg vitamin C, 160 mg bioflavonoids, 600 mg magnesium and 900 mg vitamin B complex) may improve haemostatic factors and fibrin network structures. Of the haemostatic factors measured, only median plasmin-antiplasmin complex (PAP) and thrombin-antithrombin complex (TAT) concentrations were both significantly decreased with FoodState Vitamin C complex compared with placebo [PAP, -4.05% (-23.39, -0.23) versus 1.81% (-8.95, 8.09); TAT, -5.81% (-18.47, 0.39) versus 0.12% (-8.03, 13.5)]. As for fibrin network structures, only compaction was significantly increased from baseline to end [49.95% (47.55, 53.70) to 51.85% (48.55, 56.65)] by FoodState Vitamin C complex supplementation. No significant changes were found in plasma fibrinogen, plasminogen activator inhibitor 1 activity, tissue plasminogen activator antigen, D-dimer, serum lipids or lipoprotein (a) concentrations. In conclusion, the decreases in TAT and PAP are possibly an indication that the FoodState Vitamin C complex decreased the initiation of haemostasis, which in turn led to a compensatory reduction in fibrinolysis. FoodState Vitamin C complex may therefore be protective of cardiovascular disease by causing a new reduced steady state of haemostatic balance and less rigid clots (increased compaction).
Loots
Deirdré
D
School of Physiology, Nutrition and Consumer Science, North-West University, Potchefstroom, South Africa.
Oosthuizen
Welma
W
Pieters
Marlien
M
Spies
Christelle
C
Vorster
Hester H
HH
D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005337:Fibrin / Q000737:chemistry / Q000187:drug effects*; D005341:Fibrinolysin / Q000032:analysis; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D000979:alpha-2-Antiplasmin / Q000032:analysis
D015415:Biomarkers; D008055:Lipids; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D005337:Fibrin; D010447:Peptide Hydrolases; D005341:Fibrinolysin; D001205:Ascorbic Acid